Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityHRMNU / Harmony Merger Corp. (413247206)
Chairperson and CEOEisbrenner Kathleen
Institutional Owners31
Institutional Shares95,021,247 - 89.31%
Common Stock Shares Outstanding106,400,000 shares (as of 2018-03-31)
Institutional Value$ 460,038,000 USD
Related HRMNW / Harmony Merger Corp.
HRMN / Harmony Merger Corp.
NEXT / NextDecade Corporation

Institutional Stock Ownership and Shareholders()

HRMNU / Harmony Merger Corp. Institutional Ownership

Harmony Merger Corp. (NASDAQ:HRMNU) has 31 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 95,021,247 shares. Largest shareholders include York Capital Management Global Advisors, LLC, Valinor Management, Llc, Halcyon Management Partners LP, General Electric Co, Highland Capital Management Lp, Vanguard Group Inc, Perella Weinberg Partners Capital Management LP, Rotation Capital Management, LP, TPH Asset Management, LLC, and Covalent Partners LLC.
Harmony Merger Corp. (NASDAQ:HRMNU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/hrmnu"><img src="https://images.fintel.io/us-hrmnu-so.png" alt="HRMNU / Harmony Merger Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 2,089,555 2,089,555 0.00 17,385 10,322 -40.63
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 54,153 163,526 201.97 451 808 79.16
2018-05-08 13F-HR Neuberger Berman Group LLC 13,178 0 -100.00 110 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 8,216 5,099 -37.94 68 25 -63.24
2018-05-15 13F-HR BlueCrest Capital Management Ltd 55,497 20,620 -62.84 462 102 -77.92
2018-05-15 13F-HR Perella Weinberg Partners Capital Management LP 688,638 3,402
2017-08-14 13F-HR/A Rotation Capital Management, LP 381,596 381,596 0.00 305 305 0.00
2018-05-15 13F-HR STATE STREET CORP 118,100 583
2018-05-15 13F-HR GENERAL ELECTRIC CO 3,211,121 2,969,350 -7.53 26,717 14,669 -45.09
2018-05-15 13F-HR BARCLAYS PLC 1,514 7
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 35,251 35,033 -0.62 294 173 -41.16
2018-05-15 13F-HR VANGUARD GROUP INC 1,605,848 888,467 -44.67 13,361 4,389 -67.15
2018-05-15 13F-HR Halcyon Management Partners LP 9,418,153 9,404,403 -0.15 78,359 46,458 -40.71
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 33,138 41,443 25.06 276 205 -25.72
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 42 10,466 24,819.05 0 52
2018-04-18 13F-HR/A FNY Managed Accounts LLC 500 0 -100.00 4 0 -100.00
2018-02-14 13F-HR TPH Asset Management, LLC 190,817 371,835 94.86 1,925 3,094 60.73
2018-05-15 13F-HR Verition Fund Management LLC 18,210 90
2018-05-15 13F-HR PIONEER INVESTMENT MANAGEMENT INC 4,286 0 -100.00 36 0 -100.00
2018-05-14 13F-HR York Capital Management Global Advisors, LLC 57,681,503 57,599,003 -0.14 318,999 275,461 -13.65
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 179,897 181,822 1.07 1,496 898 -39.97
2018-07-17 13F-HR DEPRINCE RACE & ZOLLO INC 42,600 57,000 33.80 210 390 85.71
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 0 11 0 0
2018-05-15 13F-HR Bank of New York Mellon Corp 10,470 0 -100.00 87 0 -100.00
2018-05-15 13F-HR VALINOR MANAGEMENT, LLC 19,486,063 19,457,313 -0.15 162,124 96,120 -40.71
2018-05-23 13F-HR/A Polar Asset Management Partners Inc. 80,000 80,000 0.00 599 357 -40.40
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 36,425 38,648 6.10 304 191 -37.17
2018-05-15 13F-HR DEUTSCHE BANK AG\ 8,072 14,500 79.63 67 71 5.97
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 12,418 127,880 929.80 103 632 513.59
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 54 0
2018-05-09 13F-HR NORTHERN TRUST CORP 15,976 79
2018-05-14 13F-HR K2 PRINCIPAL FUND, L.P. 0 40,000 0 198
2018-05-15 13F-HR Covalent Partners LLC 182,231 182,231 0.00 1,410 864 -38.72
2018-05-15 13F-HR Paloma Partners Management Co 12,900 14,054 8.95 107 69 -35.51
2018-05-17 13F-HR Atlantic Trust Group, LLC 4,900 4,900 0.00 41 24 -41.46

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

U.S. IPO Weekly Recap: Sonos Files For An IPO During Quiet Holiday Week

2018-07-07 seekingalpha
The US IPO market was quiet this week thanks to the July 4th holiday. Just one blank check company completed a public offering. The big news this week came from connected speaker company Sonos, which filed for an estimated $250 million IPO. (30-0)

CUSIP: 413247206